Vericel® Corporation

About Vericel® Corporation

Vericel® Corporation is a leading biotechnology company focused on developing and commercialising innovative cell therapies for the treatment of patients with severe diseases and conditions. Established with a vision to transform patient care, Vericel® is dedicated to advancing the field of regenerative medicine.

The company’s flagship products include Epicel®, a cultured epidermal autograft for the treatment of patients with deep partial-thickness and full-thickness burns, and MACI®, a cell-based product for the repair of cartilage defects in the knee. These products exemplify Vericel®’s commitment to providing effective solutions that enhance healing and improve quality of life.

Vericel® operates with a strong emphasis on research and development, continually striving to innovate and expand its product offerings. The company collaborates with leading medical professionals and institutions to ensure that its therapies meet the highest standards of efficacy and safety.

Headquartered in the UK, Vericel® Corporation is strategically positioned to serve a global market, with a focus on expanding its reach and impact in the field of regenerative medicine. The company is committed to ethical practices and sustainability, ensuring that its operations contribute positively to society.

With a dedicated team of experts and a robust pipeline of products, Vericel® Corporation is poised for growth and success in the ever-evolving landscape of biotechnology. The company’s mission is to empower patients and healthcare providers with advanced therapeutic options that promote healing and recovery.

In summary, Vericel® Corporation stands at the forefront of innovation in cell therapy, driven by a passion for improving patient outcomes and a commitment to excellence in all aspects of its operations.